BASEL, Switzerland, May 27, 2026
Roche has announced the launch of its groundbreaking Liver Disease Panel, the healthcare industry’s first comprehensive suite of certified digital algorithms designed to support the detection, assessment, and management of Chronic Liver Disease (CLD). Combining advanced biomarker diagnostics with digital health technologies, the new platform aims to help clinicians identify liver disease earlier, improve risk stratification, and support timely interventions for millions of patients worldwide. The launch marks a significant milestone in the growing convergence of artificial intelligence, digital diagnostics, and precision medicine, addressing a global healthcare burden that currently affects an estimated 1.5 billion people worldwide.
Roche Combines Digital Algorithms and Biomarkers for Earlier Diagnosis
Chronic Liver Disease remains one of the most underdiagnosed health conditions globally, often progressing silently until patients develop advanced fibrosis, cirrhosis, or liver cancer. Recognizing the urgent need for earlier detection, Roche has developed the Liver Disease Panel to provide clinicians with a comprehensive set of digital tools capable of supporting evidence-based decision-making throughout the patient care pathway.
At the heart of the platform is LiverPRO, a CE-marked algorithm developed in collaboration with health technology company Evido. The innovative solution requires only a patient’s age and a minimum of three routine blood biomarkers to assess liver fibrosis risk. By utilizing readily available laboratory data, LiverPRO enables healthcare providers to identify patients at risk much earlier than traditional diagnostic approaches, helping to accelerate referrals and clinical interventions.
The platform also integrates Roche’s advanced biomarker technologies, including Elecsys® PRO-C3, alongside clinically validated algorithms such as ADAPT, allowing clinicians to evaluate fibrosis severity with greater confidence. This combination of biomarker science and digital analytics offers a scalable and non-invasive alternative to more invasive diagnostic procedures, improving access to liver disease assessment across diverse healthcare settings.
Advertisement
Addressing the Growing Global Burden of Liver Disease
The launch comes at a critical time as the prevalence of liver disease continues to rise worldwide. According to Roche, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) now affects approximately 38% of the global population, making it one of the fastest-growing contributors to chronic liver complications and liver cancer. Because many patients remain asymptomatic during the early stages of disease progression, opportunities for intervention are frequently missed until irreversible damage has occurred.
The Liver Disease Panel is designed to address this challenge by supporting care across the entire liver disease continuum, from early fibrosis detection through advanced disease monitoring and hepatocellular carcinoma surveillance. By reducing dependence on invasive procedures and expanding access to risk assessment tools, Roche aims to promote a more proactive healthcare model focused on prevention, early diagnosis, and personalized treatment planning.
Importantly, the platform incorporates several trusted clinical scoring systems, including FIB-4 Index, MELD Score, ALBI Score, Child-Pugh Score, and Lille Model, creating a unified digital ecosystem that supports comprehensive liver disease management. These tools work together to provide clinicians with actionable insights that can improve patient outcomes and optimize healthcare resources.
Expanding Digital Health Innovation in Clinical Practice
The Liver Disease Panel is available through Roche’s navify® Algorithm Suite, a secure digital platform that integrates seamlessly into existing hospital information systems and clinical workflows. The solution enables healthcare professionals to access multiple certified algorithms from a single interface, streamlining diagnostic decision-making while maintaining strict medical device compliance and data security standards.
As healthcare systems increasingly adopt digital technologies to address growing disease burdens, Roche’s latest innovation highlights the expanding role of artificial intelligence and algorithm-driven diagnostics in routine clinical practice. By combining laboratory medicine, digital health infrastructure, and predictive analytics, the company is creating new opportunities to improve liver disease care while reducing diagnostic delays and unnecessary invasive testing.
With chronic liver disease continuing to place substantial pressure on healthcare systems globally, Roche’s new Liver Disease Panel represents a significant advancement in digital diagnostics. Through the integration of AI-powered algorithms, validated biomarkers, and non-invasive testing strategies, the platform has the potential to transform liver disease management, enabling earlier interventions, more precise clinical decisions, and ultimately better outcomes for patients facing one of the world’s most rapidly growing health challenges.
Source: Roche press release
